

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Resonance Health Limited
ABN 96 006 762 492

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ms Liza Dunne
Date of last notice	22 November 2010

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	HEALTH & TECHNOLOGY DEVELOPMENTS PTY LTD <THE DUNNE & MAY S/FUND A/C> Ms Liza Dunne personal superannuation Fund.
Date of change	16 June 2014
No. of securities held prior to change	1,213,107 Ordinary shares held in the name of Peter May and Liza Dunne. 1,940,278 Ordinary shares held in the name of Health & Technology Developments Pty Ltd as Trustee for the Dunne & May Superannuation Fund of which Ms Dunne has a beneficial interest.
Class	Ordinary
Number acquired	100,000
Number disposed	n/a

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,000 at 5 cents per share.
No. of securities held after change	1,213,107 Ordinary shares held in the name of Peter May and Liza Dunne. 2,040,278 Ordinary shares held in the name of Health & Technology Developments Pty Ltd as Trustee for the Dunne & May Superannuation Fund of which Ms Dunne has a beneficial interest.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Allotment of shares pursuant to Non-renounceable Entitlements Offer.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	n/a
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.